|
TN2013000398A1
|
|
Epoxyeicosatrienoic acid analogs and methods of making and using the same
|
|
WO2013048402A1
|
|
Thrombopoietin receptor ligands for neuroprotection
|
|
WO2011115956A1
|
|
Systems and methods for detection and prediction of brain disorders based on neural network interaction
|
|
WO2011106649A1
|
|
Method for simultaneous multi-slice magnetic resonance imaging using single and multiple channel receiver coils
|
|
WO2011044442A1
|
|
Method for determining locations of implanted electrodes with medical images
|
|
CN102459291A
|
|
Neuroprotective compounds and their use
|
|
WO2010120766A1
|
|
Engineered botulinum neurotoxin
|
|
WO2009114549A2
|
|
99mtc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical
|
|
US2008200370A1
|
|
Method of treating drug addiction using dextro-morphine
|
|
AU2007231760A1
|
|
Method and compositions for immunization with the pseudomonas V antigen
|
|
AU2007258380A1
|
|
Method for treating renal disease
|
|
US2007173449A1
|
|
Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
|
|
US2006241382A1
|
|
MRI method for producing an index indicative of brain disorders
|
|
EP1827509A2
|
|
Method of imaging cell death in vivo
|
|
US2007010732A1
|
|
Method for measuring neurovascular uncoupling in fMRI
|
|
WO2005069934A2
|
|
Peptide identification
|
|
IL165716D0
|
|
Pharmaceutical compositions containing heterocyclic adenosine receptor antagonists
|
|
AU2004289334A1
|
|
Methods of modulating angiogenesis and cancer cell proliferation
|
|
US2005227307A1
|
|
2-hydroxyethidium, methods of preparation and uses thereof
|
|
US7354432B2
|
|
Red to near-infrared photobiomodulation treatment of the visual system in visual system disease or injury
|
